PDE-4 — Drug Target

All drugs that target PDE-4 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Phosphodiesterase-4 (PDE-4) inhibitor

Marketed (2)

• Placebo-Apremilast · Amgen · Phosphodiesterase-4 (PDE-4) inhibitor · Immunology
  Apremilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
• Roflumilast conventional dosage · Asan Medical Center · Phosphodiesterase-4 (PDE-4) inhibitor · Respiratory / Pulmonology
  Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and structural cells.

Phase 3 pipeline (4)

• Roflumilast Foam 0.3% · Arcutis Biotherapeutics, Inc. · Phosphodiesterase-4 (PDE-4) inhibitor · Dermatology
  Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.
• Oral roflumilast · The University of Hong Kong · Phosphodiesterase-4 (PDE-4) inhibitor · Respiratory / Immunology
  Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and structural cells.
• Roflumilast Cream 0.05% · Arcutis Biotherapeutics, Inc. · Phosphodiesterase-4 (PDE-4) inhibitor · Dermatology
  Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.
• Roflumilast Foam · Arcutis Biotherapeutics, Inc. · Phosphodiesterase-4 (PDE-4) inhibitor · Dermatology
  Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and inflammatory cells.